Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis.

ABSTRACT: Uniform assessment of response to treatment is crucial to managing multiple myeloma (MM) and developing new therapies. Measurement of monoclonal protein forms the cornerstone of disease assessment in MM. According to International Myeloma Working Group (IMWG) guidelines, serum-free light chain (sFLC) is included in MM response assessment in patients with no measurable disease by electrophoresis and to define stringent complete response. We retrospectively analyzed the independent value of serial FLC on response and progression assessments in 839 patients with measurable disease by sFLC as well as serum/urine electrophoresis. A significant association was observed between sFLC and electrophoretic responses during initial therapy and at best response (p < 0.001). This study revealed comparab

SUBMITTER: Askari E 

PROVIDER: S-EPMC12332013 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature